Claims

1. A formulation comprising an effective amount of migalastat or salt thereof for use in increasing midwall fractional shortening (MWFS) in a patient having Fabry disease, wherein the effective amount is 100 mg to 150 mg free base equivalent (FBE ) and the formulation is administered to the patient every other day.

2. The formulation for use of claim 1, wherein the patient has impaired MWFS prior to initiating administration of the migalastat or salt thereof.

3. The formulation for use of claim 1 or 2, wherein the migalastat or salt thereof enhances α-galactosidase A activity.

4. The formulation for use of any one of claims 1-3, wherein effective amount is 123 mg FBE .

5. The formulation for use of any one of claims 1-4, wherein the effective amount is 123 mg of migalastat free base.

6. The formulation for use of any one of claims 1-4, wherein the effective amount is 150 mg of migalastat hydrochloride.

7. The formulation for use of any one of claims 1-6, wherein the formulation comprises an oral dosage form.

8. formulation for use of claim 7, wherein the oral dosage form comprises a tablet, a capsule or a solution.

9. The formulation for use of any one of claims 1-8, wherein the migalastat or salt thereof is administered for at least 12 months.

10. The formulation for use of any one of claims 1-9, wherein the migalastat or salt thereof is administered for at least 24 months.

11. The formulation for use of any one of claims 1-10, wherein the patient is an enzyme replacement therapy (ERT)-naïve patient.

12. The formulation for use of any one of claims 1-11 wherein the administration of migalastat or a salt thereof provides an average increase in MWFS in a group of ERT-naïve

patients with impaired MWFS of at least about 1% after 24 months of administration of migalastat or a salt thereof.

13. The formulation for use of any one of claims 1-10, wherein the patient is an ERT-experienced patient.

14. The formulation for use of any one of claims 1-13, wherein the patient has a HEK assay amenable mutation in α-galactosidase A.

15. The formulation for use of any one of claims 2-14, wherein administration of the migalastat or a salt thereof normalizes the patient's MWFS.